Animal Depression Medication; the Treatment Varies According to Cause of Condition

 

Animal Depression Medication

Animal depression medication is usually only prescribed for severely depressed behavior in animals and is generally used as a secondary or stand-by treatment, depending on the severity of the disorder. In humans, depression is usually treated with appropriate prescription drugs, cognitive behavior therapy, or ongoing counseling. It is also treated with pharmaceuticals, but these are reserved for cases of severe depression or for patients who are not responding well to conventional treatment. In most cases, antidepressants are used for the treatment of mild to moderate depression. Animals also suffer from depression due to chemical imbalance, which can be treated with animal depression medication.

However, the treatment of animal depression varies according to cause of condition. A physical examination, x-rays, and blood tests can help with the diagnosis. A veterinarian may prescribe anti-depressants or anxiety animal depression medication if the animal has chemical imbalance. Paroxetine is an anti-depressant medication used for the treatment of the panic disorder, social anxiety disorder, and major depressive disorders. It can take up to two months for a drug to be effective in treating depression. Most animals make a full recovery in around six to twelve months after being administered selective serotonin reuptake inhibitors (SSRIs).

SSRIs were launched in the mid to late 1980s. This generation of antidepressants is now the most common class used for depression. Examples include sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), paroxetine (Paxil, Pexeva), and citalopram (Celexa). However, some animal depression medications have been found to cause unpleasant side effects, such as nausea, diarrhea, constipation, dizziness, and agitation in the animals. Newer anti-depressants are being developed to avoid these side effects. Moreover, the most effective animal depression medications have fewer side effects and are better tolerated by animals than older antidepressants. The U.S. Food and Drug Administration (FDA) has approved only one anti-depressant, Clomicalm (clomipramine) for treatment of anxiety in dogs.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers aroun...
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 ...
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 ne...
Read more